RPT-Trump presidency could prove a salve for pharma merger deals

RPT-Trump presidency could prove a salve for pharma merger deals


Nov 11 Biotechnology companies, whose U.S. shares soared Wednesday after Republican Donald Trump's presidential election, may soon see another benefit: an uptick in biotech M&A. A potential influx of foreign cash and improved stock valuations under the Trump administration would likely boost dealmaking in the industry, which has been anemic ever since political rhetoric against high drug prices picked up late last year, industry analysts and investment bankers said.



from Biotech News